GSK: license agreement with Chinese WuXi Bio


(CercleFinance.com) – The Chinese pharmaceutical subcontractor WuXi Biologics announced on Thursday the signing of a license agreement with GSK, which will have the possibility to exercise up to four options on the bispecific and multi-specific TCE antibodies developed from its proprietary technology.

Under the terms of the agreement, GSK will be able to resume the development and commercialization of these antibodies targeting tumor associated antigen (TAA) and CD3 tumor antigen, currently in the preclinical phase.

WuXi Biologics is expected to receive an initial payment of $40 million, which could be supplemented by some $1.5 billion in milestone payments related to the achievement of commercial and regulatory goals.

WuXi Biologics is also eligible for the payment of royalties on product sales that may result from this license agreement.

Copyright © 2023 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.





Facebook


LinkedIn


E-mail





Source link -85